A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
- First Online:
- 447 Downloads
Nilotinib is a second-generation BCR-ABL kinase inhibitor with improved potency and selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to evaluate the efficacy, safety, and pharmacokinetics of nilotinib in Japanese patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). A total of 34 patients were evaluated in this analysis and had a median duration of drug exposure of 293 (range 13–615) days. All 6 CML-CP patients without complete hematologic response (CHR) at baseline rapidly achieved CHR. A major cytogenetic response was achieved in 94% of patients with CML-CP, including a complete cytogenetic response in 69%. A major molecular response was achieved by 56%. These responses were also observed in patients with CML in advanced stages and Ph+ ALL. Non-hematologic adverse events were mostly mild to moderate. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 50 and 28% of patients, respectively. Overall, the results of this study suggest that nilotinib induced significant responses in imatinib-resistant or -intolerant patients with CML-CP and CML in advanced stages and Ph+ ALL. The results of this study confirmed the efficacy and safety of nilotinib in Japanese patients.
KeywordsNilotinib CML BCR-ABL Imatinib resistant Ph+ ALL
- 3.Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1998;25:49–61.Google Scholar
- 7.Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. Advance online publication 12 Mar 2009. doi:10.1038/leu.2009.38.
- 8.Manley PW, Brüggen J, Fabbro D, et al. Extended kinase profiling of the Bcr-Abl inhibitor nilotinib. Proc Am Assoc Cancer Res. 2007;48:772. Abstract 3249.Google Scholar
- 10.Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–6. doi:10.1182/blood-2007-03-080689.PubMedCrossRefGoogle Scholar
- 11.Kantarjian HM, Hochhaus A, Cortes J, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood. 2007;110:226a. (Abstract 735).Google Scholar
- 12.le Coutre P, Giles FJ, Apperley J, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib resistance or intolerance accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834–9. doi:10.1182/blood-2007-04-083196.PubMedCrossRefGoogle Scholar
- 13.Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood. 2007;110:310a. (Abstract 1025).Google Scholar
- 14.Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood. 2007;110:(Abstract 2815).Google Scholar
- 15.Tojo A, Miyazaki Y, Usui N, et al. Phase I study of nilotinib in patients from Japan with imatinib-resistant Ph+ chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL). J Clin Oncol. 2007;25:(Abstract 17511).Google Scholar